- Mechanism
- Stimulates pituitary GH secretion via GHRH receptor binding
- Typical research dose
- 2 mg/day subcutaneous
- Route
- subcutaneous
- Half-life
- ~26 to 38 minutes
- Legal status
- FDA Approved
Overview
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to secrete endogenous growth hormone. As an FDA-approved medication marketed under the brand name Egrifta, this peptide is primarily utilized to reduce excess visceral adipose tissue in patients with HIV-associated lipodystrophy. The Tesamorelin peptide matters because it provides targeted fat loss without significantly altering glucose metabolism, offering a unique therapeutic profile compared to direct human growth hormone administration.
Potential Benefits
- Visceral Fat Reduction: Clinical trials demonstrate that the Tesamorelin peptide significantly reduces visceral adipose tissue in patients with HIV-associated lipodystrophy [Dhillon S, 2011].
- Improved Fat Quality: Research indicates that it improves overall fat quality and density independent of changes in total fat quantity [Lake JE et al., 2021].
- Liver Fat Reduction: Phase 2 clinical trials show efficacy in reducing hepatic fat in patients with nonalcoholic fatty liver disease (NAFLD) [NCT03375788].
- Muscle Preservation: By stimulating natural growth hormone release, it may help preserve lean muscle mass and improve physical function [NCT06554717].
- Favorable Metabolic Profile: Unlike direct growth hormone therapy, Tesamorelin maintains a more stable glucose profile and reduces the risk of severe insulin resistance [Spooner LM et al., 2012].
Where to Buy Tesamorelin
Research compound. Tesamorelin is a research chemical, typically not FDA-approved for human consumption. Sale or use for human consumption may be illegal in your jurisdiction.
No compensation. PeptideStack does not endorse, verify, or receive compensation from any vendor. No affiliate or referral relationships.
Verify third-party COAs and consult a qualified healthcare provider before using any compound.
Side Effects
Common side effects:
- Injection site reactions (erythema, pruritus, pain)
- Arthralgia (joint pain) and myalgia (muscle pain)
- Peripheral edema (swelling in the extremities)
- Mild, transient increases in blood glucose levels
- Night sweats or flushing
Rare or serious side effects:
- Hypersensitivity reactions or anaphylaxis
- Development of neutralizing antibodies
- Increased risk of malignancies associated with elevated IGF-1
- Significant glucose intolerance or diabetes exacerbation
Tesamorelin is FDA-approved but should only be used under medical supervision. Consult a qualified healthcare provider before use.
Mechanism of Action
Receptor activation drives the primary mechanism of the Tesamorelin peptide. Upon subcutaneous administration, it binds to growth hormone-releasing hormone (GHRH) receptors located in the anterior pituitary gland. This binding stimulates the synthesis and pulsatile release of endogenous growth hormone (GH) into the systemic circulation, mimicking the body's natural physiological rhythms [Wang Y et al., 2009].
Lipolytic signaling occurs as a downstream effect of elevated circulating growth hormone levels. The increased GH binds to specific receptors on adipocytes, particularly in visceral fat deposits, triggering lipolysis and reducing triglyceride accumulation. Furthermore, this pathway increases insulin-like growth factor 1 (IGF-1) levels without causing the severe negative feedback loop often associated with exogenous recombinant human growth hormone [Grunfeld C et al., 2011].
Origin & History
Synthetic development of Tesamorelin was pioneered by Theratechnologies Inc. to create a more stable and effective GHRH analogue. Researchers modified the natural 44-amino acid sequence of human GHRH by adding a trans-3-hexenoic acid group to the N-terminus, significantly increasing its resistance to degradation by dipeptidyl peptidase-4 (DPP-4) and extending its half-life. This structural enhancement allowed for practical once-daily subcutaneous dosing.
Regulatory approval marked a major milestone when the FDA approved the peptide under the brand name Egrifta in 2010. It was specifically authorized for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [FDA Label]. Since its approval, ongoing clinical trials have continued to explore Tesamorelin benefits for other metabolic conditions, including nonalcoholic fatty liver disease and COPD-related muscle wasting [NCT01388920].